Partnered Liquid Tumor-1 is under clinical development by Isogenica and currently in Phase I for Hematological Tumor. According to GlobalData, Phase I drugs for Hematological Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Partnered Liquid Tumor-1 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Partnered Liquid Tumor-1 overview
Antibody is under development for the treatment of hematological tumor. The therapeutic candidate is being developed based on single domain antibody platform.
Isogenica overview
Isogenica is a biotechnology contract research organisation (CRO) that specialises in the discovery of small-format antibodies, nanobodies, sdAbs, or heavy-chain single domains. The company’s main activities focuses on the use of its proprietary CIS display technology and synthetic VHH libraries. These resources are used to accelerate antibody discovery and development, offering robust, flexible, and scalable solutions. Isogenica’s products and services serves across various industries, particularly in the development of bi-specifics, ADCs, cell and gene therapies, targeted protein degraders, and diagnostics. Isogenica is headquartered in Saffron Walden, Essex, the UK.
For a complete picture of Partnered Liquid Tumor-1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
